Your browser is no longer supported. Please, upgrade your browser.
Settings
DMTK DermTech, Inc. daily Stock Chart
DMTK [NASD]
DermTech, Inc.
Index- P/E43.80 EPS (ttm)0.14 Insider Own- Shs Outstand10.53M Perf Week14.50%
Market Cap63.18M Forward P/E- EPS next Y- Insider Trans- Shs Float6.66M Perf Month-72.22%
Income0.70M PEG- EPS next Q- Inst Own12.00% Short Float0.14% Perf Quarter-70.30%
Sales2.48M P/S25.48 EPS this Y396.40% Inst Trans-0.63% Short Ratio0.46 Perf Half Y-70.30%
Book/sh1.09 P/B5.50 EPS next Y- ROA- Target Price- Perf Year-69.14%
Cash/sh0.00 P/C- EPS next 5Y- ROE- 52W Range4.52 - 23.24 Perf YTD-70.62%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-74.78% Beta-
Dividend %- Quick Ratio0.00 Sales past 5Y- Gross Margin- 52W Low29.65% ATR0.96
Employees36 Current Ratio0.00 Sales Q/Q-9.60% Oper. Margin- RSI (14)24.43 Volatility12.25% 17.05%
OptionableNo Debt/Eq0.00 EPS Q/Q-19.60% Profit Margin- Rel Volume1.23 Prev Close6.00
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume19.84K Price5.86
Recom- SMA20-15.60% SMA50-61.53% SMA200-69.11% Volume24,364 Change-2.33%
Sep-16-19 04:30PM  DermTech Announces Appointment of Kevin Sun as Chief Financial Officer Business Wire
DermTech, Inc., a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California.